Autopsy report · NCT00252837

GALLANT 22 Tesaglitazar vs. Placebo

“The development program has been terminated”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months after it had already started.
• Ran for about 1 year 8 months before it stopped.
• 475 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

AstraZeneca

Sponsor type

Industry

Conditions

Type 2 Diabetes

Interventions

Tesaglitazar; Dietary and Lifestyle counseling

Participants

475

Sites

101

Countries

Australia, Czechia, Estonia, France, Greece, Hungary, Latvia, Lithuania, Norway, Philippines, Poland, Serbia and Montenegro and more

Trials that died the same way

• A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
  “Development program terminated.” (94% match in meaning)
• A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
  “Program Development discontinued” (71% match in meaning)
• Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer
  “Program terminated” (70% match in meaning)
• A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
  “Terminated due to budgetary considerations and length of development.” (64% match in meaning)
• Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
  “Development discontinued” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.